key: cord-0767240-nzrann41 authors: Castillo-Bravo, R.; Lucca, N.; Lai, L.; Marlborough, K.; Brychkova, G.; Lonergan, C.; O'Grady, J.; Alikhan, N.-F.; Trotter, A.; Page, A.; Smyth, B.; McKeown, P. C.; Feenstra, J.; Ulekleiv, C.; Sorel, O.; Gandhi, M.; Spillane, C. title: Clinical Performance of Direct RT-PCR Testing of Raw Saliva for Detection of SARS-CoV-2 in Symptomatic and Asymptomatic Individuals date: 2022-05-16 journal: nan DOI: 10.1101/2022.05.15.22275086 sha: 4d2d5b9d2989e4c536bfb24ae4c0bcf87fc82e5f doc_id: 767240 cord_uid: nzrann41 RT-qPCR tests based on RNA extraction from nasopharyngeal swab samples are promoted as the gold standard for SARS-CoV-2 detection. However, self-collected saliva samples offer a non-invasive alternative more suited to high-throughput testing. This study evaluated the performance of TaqPath COVID-19 Fast PCR Combo Kit 2.0 assay for detection of SARS-CoV-2 in raw saliva relative to a lab-developed direct RT-qPCR test (SalivaDirect-based PCR) and a RT-qPCR test based on RNA extraction from NPS samples. Both samples were collected from symptomatic and asymptomatic individuals (N=615). Saliva samples were tested for SARS-CoV-2 using the TaqPath COVID-19 Fast PCR Combo Kit 2.0 and the SalivaDirect-based PCR, while RNA extracts from NPS samples were tested by RT-qPCR according to the Irish national testing system. The TaqPathTM COVID-19 Fast PCR detected SARS-CoV-2 in 52 saliva samples, of which 51 were also positive with the SalivaDirect-based PCR. 49 samples displayed concordant results with the NPS extraction-based method, while three samples were positive on raw saliva. Among the negative samples, 10 discordant cases were found with the TaqPath COVID-19 Fast PCR (PPA 85.7%; NPA 99.5%), when compared to the RNA extraction-based NPS method, performing similarly to the SalivaDirect-based PCR (PPA 87.5%; NPA 99.5%). The direct RT-qPCR testing of saliva samples shows high concordance with NPS extraction-based method for SARS-CoV-2 detection, providing a cost-effective and highly-scalable system for high-throughput COVID-19 rapid-testing. The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Wuhan in 45 2019 led to a global pandemic of coronavirus disease 2019 . SARS-CoV-2 can lead 46 to both symptomatic and asymptomatic infections, making detection of infected individuals 47 challenging if based solely on symptomatic diagnostic testing. To combat viral spread and ensure 48 public health, countries have implemented different strategies related to diagnostic, screening 49 and surveillance testing. COVID-19 tests should exhibit high sensitivity and quick turn-around-50 times to adapt treatment, reduce the spread of disease, and adjust public health interventions to 51 the local epidemiology. Establishing COVID-19 testing in high-throughput settings such as 52 schools or workplaces also requires tests that are easy to use, that require minimal resources and 53 have a high acceptance rate by the individuals involved in the testing 1 . 54 55 Detection of SARS-CoV-2 in RNA extracted from nasopharyngeal swab (NPS) samples using 56 quantitative RT-qPCR is considered to be the gold standard for identification of infection, as the virus typically infects the upper respiratory tract. However, reliable collection of 58 NPS requires trained health care professionals, and NPS samples can be difficult to obtain from 59 some individuals due to the discomfort associated with the technique. Using saliva as an 60 alternative sample type to NPS offers several advantages, including non-invasive self-collection, 61 reduced risk of viral transmission and lower sample costs in terms of trained health care 62 personnel, personal protective equipment and costs associated with sample collection 2 . 63 64 A number of studies have shown that saliva and NPS RT-PCR-based tests exhibited comparable 65 analytical performance 3-10 . In addition, several reports indicate that saliva might be more 66 sensitive than nasopharyngeal or nasal swabs for diagnosis of SARS-CoV-2 infection, especially 67 for asymptomatic cases or with the emergence of new SARS-CoV-2 variants that can have a 68 different tropism compared to earlier variants 7, 11-13 . Indeed, the 2021 guidance on the use of 69 saliva as sample material for COVID-19 testing highlighted the potential of saliva for nucleic 70 acid based (i.e. PCR based) SARS-CoV-2 testing, while cautioning on the use of saliva as a 71 sample for rapid antigen or antibody tests 14 asymptomatic, while the information on the symptomatic status was not available for the 86 remaining part of the cohort ( Figure 1A) . The Asymptomatic or Symptomatic status of each 87 individual was assigned based on answer given to the question "Reason why you are being tested 88 by the HSE" in the registration form that was provided to each volunteers. Each individual who 89 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 16, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 indicated that they had a cough and/or high temperature were classified as symptomatic, while 90 others were classified as asymptomatic (such individuals had been referred for testing as they 91 had been contact traced in accordance with the government guidelines of the time). All saliva 92 samples were tested upon collection using the SalivaDirect-based RT-PCR. Concurrent to saliva 93 collection, NPS were collected and tested for SARS-CoV-2 presence using an RNA extraction-94 based method according to the national COVID-19 testing system in Ireland run by the Health 95 Service Executive (HSE). Following circa 9 months of storage at -20 °C, raw saliva samples 96 were thawed and re-tested using the lab's SDB RT-qPCR as well as the TaqPath™ (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 16, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 across 3 SARS-CoV-2 genes (Orf1a, Orf1b and N) to ensure accurate detection of SARS-CoV-2 113 as new mutations continue to arise. RT-qPCR was performed on the QuantStudio™ 5 Real Time 114 PCR Instrument with QuantStudio™ Design and Analysis software v1.5.1, and results were 115 analyzed using the Pathogen Interpretive Software CE-IVD Edition 1.1.0. NPS samples were 116 tested within the national HSE testing program using an RNA extraction-based RT-PCR with the 117 TaqPath TM COVID-19 CE-IVD RT-PCR kit. The study design is shown in Figure 1B . CoronaHiT 16 . WGS was performed using the Illumina NextSeq 500 platform with one positive 126 control and one negative control. The raw reads were demultiplexed using bcl2fastq (v2.20). The 127 reads were used to generate a consensus sequence using the ARTIC bioinformatic pipeline 128 (https://github.com/connor-lab/ncov2019-artic-nf). Briefly, the reads had adapters trimmed with 129 TrimGalore 17 , and were aligned to the Wuhan Hu-1 reference genome (accession MN908947.3) 130 using BWA-MEM (v0.7.17) 18 ; the ARTIC amplicons were trimmed and a consensus built using 131 iVAR (v.1.3.0) 19 . Genomes that contained more than 10% missing data were excluded from 132 further analysis to ensure high quality phylogenetic analysis. PANGO lineages were assigned 133 using Pangolin (v2.3.2) (https://github.com/cov-lineages/pangolin) and PangoLEARN model 134 dated 2021-02-21 20 . 135 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. RT-qPCR on raw saliva shows concordance with RT-qPCR on NPS-extracted RNA for 139 A total of 615 raw saliva samples obtained from symptomatic and asymptomatic individuals 141 were tested following long-term storage at -20 °C using both the TaqPath TM COVID-19 Fast 142 PCR Combo Kit 2.0 and the lab's SDB-PCR test. At the time of saliva sample collection, all 143 individuals also provided NPS samples which were tested using an extraction-based RT-qPCR 144 test in an HSE diagnostic laboratory. For all individuals in the study, the result of the RT-qPCR 145 test from the nasopharyngeal swab sample was available. All raw saliva samples were tested 146 both at the time of collection and again following long-term storage at -20 °C using the SDB RT-147 qPCR assay without an RNA extraction step. For all samples matching results were obtained at 148 the time of sampling and at the time of repeated testing following long-term storage using the 149 SDB RT-qPCR, indicating that no deterioration of sample had occurred. 150 To evaluate the performance of the direct RT-qPCR testing approach of raw saliva for detection 152 of SARS-CoV-2, results obtained by testing with the TaqPath TM COVID-19 Fast PCR Combo 153 Kit 2.0 were compared to the results based on the nasopharyngeal swab testing using an 154 extraction-based RT-qPCR method (Table 1) . SARS-CoV-2 was detected using the TaqPath TM 155 COVID-19 Fast PCR Combo Kit 2.0 in 52 raw saliva samples from the cohort panel, of which 156 51 were in full agreement with both the SDB-PCR results at the time of collection and re-testing 157 following storage at -20 °C. Interestingly, two samples tested positive only from raw saliva 158 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 16, 2022. ; https://doi.org/10. 1101 /2022 . In both cases they tested positive consistently for both the TaqPath TM COVID-19 159 Fast assay and the SDB-PCR, while the RNA extraction-based testing of the NPS in these cases 160 yielded a negative result. 161 The performance of the lab's SDB RT-qPCR in raw saliva samples was also evaluated in 162 comparison to the nasopharyngeal swab testing using an extraction-based RT-qPCR method 163 (Table 2) (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. symptoms. In the current study we demonstrate that direct RT-qPCR from raw saliva samples 214 using either our in-house developed SDB-PCR assay or a commercially available CE-IVD 215 marked TaqPath Fast kit enables accurate detection of SARS-CoV-2 in both symptomatic and 216 asymptomatic individuals with PPA of >83% and NPA of >99% when compared to the "gold-217 standard" RNA extraction-based RT-qPCR from nasopharyngeal swabs (Figure 2 ). Despite the 218 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. confirmed patients even provide greater detection sensitivity and consistency due to an 235 approximately 5X higher viral load compared to nasopharyngeal swabs 10 . Indeed, saliva can 236 offer higher sensitivity and lower variability of saliva testing when compared to the NPS 237 specimens 2, 11 . Our results also demonstrated that two saliva samples gave a positive result using 238 both of the saliva-based direct PCR methods, one of which was confirmed by WGS, while these 239 same samples tested negative on the extraction-based RT-PCR testing of matched 240 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 16, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 nasopharyngeal swabs. This finding suggests that saliva samples may result in greater accuracy 241 from PCR-based testing than nasopharyngeal swabs. 242 In addition to structural differences between variants at the nucleic or polypeptide levels, instance, one study tested different RT-LAMP testing methods using saliva or NPS as sample, 260 and found similar results when using purified/precipitated RNA from each sample type but with 261 significantly reduced sensitivity when the sample is used directly (a reduction from 93% to 262 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 16, 2022. ; https://doi.org/10.1101/2022.05.15.22275086 doi: medRxiv preprint 65%) 29 . Similar results for direct RT-LAMP were obtained by other groups, indicating 263 significantly lower sensitivity of such approach compared to direct RT-PCR 29-31 . 264 265 A desirable feature of any diagnostic kit is the ability to detect different variants, particularly for 266 the case of RNA viruses such as SARS-CoV-2 that are prone to mutation and recombination. 267 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 16, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 The current COVID-19 pandemic has highlighted the need for diagnostic testing, screening and 286 surveillance methods that are high-throughput and cost-effective. While point-of-care antigen 287 testing has been deployed at scale globally, the reality is that the detection limit of antigen tests 288 remains poorer than PCR-based methods. However, increasing the throughput of PCR-based 289 testing for more accurate detection of SARS-CoV-2 has been constrained by the use of NPS 290 which are costly and cumbersome to collect. In this study, we demonstrated that highly accurate 291 PCR-based testing can be conducted directly on saliva samples, using a Saliva-Direct based test 292 and a novel CE-IVD marked TaqPath™ COVID-19 Fast PCR Combo Kit 2.0. Saliva-based 293 testing for SARS-CoV-2 provides a highly scalable and accurate approach for rapid detection of 294 SARS-CoV-2 especially during surges of COVID-19 cases, for large-scale mass-testing which 295 includes screening and surveillance programs. 296 297 This study was funded by Science Foundation Ireland grant no. 20/COV/0198 and 21/COV/3753 to 299 CS. We are very grateful to Anne Wyllie (Yale University) and Michael Crone (Imperial 300 College) for support and advice on this work. We are also grateful to the Health Service 301 Executive of Ireland for assistance in sampling. 302 303 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The nasopharyngeal swabs were processed on the same or following day, while the saliva testing was performed on 433 samples following storage at -20 °C for several months. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. were processed on the same or following day, while the saliva testing was performed on samples following storage at -20 °C for several months. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 16, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 COVID-19 testing: One size does not fit all Saliva or nasopharyngeal swab 308 specimens for detection of SARS-CoV-2 314 Comparison of Saliva and Nasopharyngeal Swab Nucleic Acid Amplification Testing for 315 Detection of SARS-CoV-2: A Systematic Review and Meta-analysis Investigation of saliva, tongue swabs and buccal 318 swabs as alternative specimen types to nasopharyngeal swabs for SARS-CoV-2 testing Self-collected unstimulated saliva, oral swab, 322 and nasopharyngeal swab specimens in the detection of SARS-CoV-2 Saliva as a Noninvasive 325 Specimen for Detection of SARS-CoV-2 Saliva in the 328 Diagnosis of COVID-19: A Review and New Research Directions Saliva May Be Considered as Reliable Tool 331 for Diagnosis of COVID-19 When Compared With Nasopharynx or Throat Swabs Saliva is 13 Control ECfDPa: Considerations for the use of saliva as sample material for COVID-19 352 testing. Stockholm: ECDC, 2021. 353 15. Quick J: NCoV-2019 Sequencing Protocol v3 (LoCost). Protocolsio 2020. 354 16 358 CoronaHiT: high-throughput sequencing of SARS-CoV-2 genomes Aligning Sequence Reads, Clone Sequences and Assembly Contigs with BWA-362 MEM An amplicon-based sequencing framework for 366 accurately measuring intrahost virus diversity using PrimalSeq and iVar Group ftUoMSR: 374 Comparison of Saliva and Mid-Turbinate Swabs for Detection of COVID-19 Saliva sample as a non-invasive 378 specimen for the diagnosis of coronavirus disease 2019: a cross-sectional study Asymptomatic Persons for Severe Acute Respiratory Syndrome Coronavirus 2 Using 383 Saliva Saliva Sampling and Its Direct Lysis, an Excellent 387 Option To Increase the Number of SARS-CoV-2 Diagnostic Tests in Settings with 388 Supply Shortages SalivaDirect: A simplified 394 and flexible platform to enhance SARS-CoV-2 testing capacity A Direct Comparison of Enhanced Saliva to Nasopharyngeal Swab for the 398 Detection of SARS-CoV-2 in Symptomatic Patients Viral Load Difference between 400 Symptomatic and Asymptomatic COVID-19 Patients: Systematic Review and Meta-401 Analysis Clinical Evaluation of 407 Self-Collected Saliva by Quantitative Reverse Transcription-PCR (RT-qPCR), Direct 408 RT-qPCR Antigen Test To Diagnose COVID-19 CoV-2 detection by fluorescence loop-mediated isothermal amplification with and 413 without RNA extraction Antigenic evolution will lead to new SARS-415 CoV-2 variants with unpredictable severity CoV-2 Delta variant containing mutation in the probe binding region used for RT-qPCR 418 test in Japan exhibited atypical PCR amplification and might induce false negative result No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity